CN112480079B - 化合物及其治疗癌症的用途 - Google Patents
化合物及其治疗癌症的用途 Download PDFInfo
- Publication number
- CN112480079B CN112480079B CN202011433095.8A CN202011433095A CN112480079B CN 112480079 B CN112480079 B CN 112480079B CN 202011433095 A CN202011433095 A CN 202011433095A CN 112480079 B CN112480079 B CN 112480079B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cancer
- brm2
- esi
- 400mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 18
- 201000011510 cancer Diseases 0.000 title claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 150000003254 radicals Chemical class 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- -1 stereoisomers Chemical class 0.000 abstract description 86
- 239000012453 solvate Substances 0.000 abstract description 27
- 239000000651 prodrug Substances 0.000 abstract description 23
- 229940002612 prodrug Drugs 0.000 abstract description 23
- 150000002148 esters Chemical class 0.000 abstract description 22
- 150000002170 ethers Chemical class 0.000 abstract description 16
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 121
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 238000004949 mass spectrometry Methods 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 73
- 238000006243 chemical reaction Methods 0.000 description 70
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 66
- 238000001819 mass spectrum Methods 0.000 description 65
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 42
- 238000010898 silica gel chromatography Methods 0.000 description 42
- 125000003118 aryl group Chemical group 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 238000001035 drying Methods 0.000 description 35
- 239000012074 organic phase Substances 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 238000005406 washing Methods 0.000 description 25
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 229910052799 carbon Inorganic materials 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 238000010438 heat treatment Methods 0.000 description 20
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 125000006413 ring segment Chemical group 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 8
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 125000003373 pyrazinyl group Chemical group 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000009987 spinning Methods 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- DTNIVPNKBVTAPK-UHFFFAOYSA-N 2-(4-fluorophenyl)-9-(2-oxo-1H-pyridin-3-yl)-8,9-dihydro-6H-triazolo[4,5-f]quinolin-7-one Chemical compound Fc1ccc(cc1)-n1nc2ccc3NC(=O)CC(c4ccc[nH]c4=O)c3c2n1 DTNIVPNKBVTAPK-UHFFFAOYSA-N 0.000 description 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- 101150106849 BRG1 gene Proteins 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 229910017852 NH2NH2 Inorganic materials 0.000 description 2
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- JQCXWCOOWVGKMT-UHFFFAOYSA-N diheptyl phthalate Chemical compound CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC JQCXWCOOWVGKMT-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005059 halophenyl group Chemical group 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- KQCOAUIIARKIRY-UHFFFAOYSA-N 1,2-dichloro-1,1-difluorohexane Chemical compound CCCCC(Cl)C(F)(F)Cl KQCOAUIIARKIRY-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- XQYVOLNWZPSTGZ-UHFFFAOYSA-N 2-fluoro-n-[5-oxo-2-phenyl-4-(trifluoromethyl)-1h-imidazol-4-yl]benzamide Chemical compound FC1=CC=CC=C1C(=O)NC1(C(F)(F)F)C(=O)NC(C=2C=CC=CC=2)=N1 XQYVOLNWZPSTGZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPRMFUAMSRXGDE-UHFFFAOYSA-N ac1o530g Chemical compound NCCN.NCCN DPRMFUAMSRXGDE-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 101150105432 brm gene Proteins 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- LKTJPAUDNOBJAZ-UHFFFAOYSA-N chembl503606 Chemical compound OC1=CC=CC=C1C1=NNC=C1 LKTJPAUDNOBJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明提供了式(I)的化合物或其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,所述的化合物能够用于预防和/或治疗癌症,
Description
技术领域
本发明属于医药领域,涉及一种预防和/或治疗癌症的化合物及其制备方法。
背景技术
BRG1和BRM是哺乳动物染色质重构复合物SWI/SNF的核心ATP酶亚单位,两者结构相似、功能互补。BRG1的ATP水解酶结构域可以结合并水解ATP提供能量,使染色质重构复合物结合到染色质上介导DNA从核小体上解离从而调节基因的转录。BRG1的C-末端是一个组蛋白密码的reader结构域,它可以特异性的识别乙酰化修饰的赖氨酸,该过程对于染色质重构复合物结合到正确的染色质位点至关重要。
已有研究认为,BRG1参与调控一些和肿瘤发生发展转录突变,如CD44、c-fos等,而且在肺癌、膀胱癌、乳腺癌、前列腺癌、胃癌等癌症中,BRG1是发病重要的抑癌基因。另外,TakahiroOike等人也报道BRM蛋白可以作为BRG1缺乏型肺癌治疗的候选靶点。通过免疫组化分析方法显示,约10%的非小细胞肺癌(NSCLCs)患者中存在BRG1-缺乏和BRM过表达的现象,因此证明针对BRM靶点的疗法具有可行性,并且BRG1的缺失也发生在其他癌症中,包括胰腺,皮肤和脑癌,例如BRG1最近被确定为在成神经管细胞瘤中经常突变的基因,由此针对BRM蛋白的靶向治疗可适用于治疗各种癌症。
CN105523955A公开了一系列用于癌症治疗的化合物,特别是对于BRG1基因缺失的非小细胞肺癌具有治疗作用,然而其中披露的化合物仍然存在活性不足以及成药性差的缺陷,特别是对于2-(1H-吡唑-3-基)苯酚类型的化合物而言,吡唑环上的取代基仅能够适用于烷基取代基团,极大的限制了应用范围。
发明内容
本发明的一个方面提供式(I)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
其中,
R1选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基时,R2选自C2-10烯基、C2-10炔基,其中所述烷基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)芳香基、-N(C0-10烷基)杂环芳香基、芳基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R1选自H、C1-6烷基时,R2选自C2-6烯基、C2-6炔基,其中所述烯基或炔基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、苯基,
更优选的,R1选自H、C1-3烷基时,R2选自C2-6烯基,其中所述烯基或炔基上的一个碳原子可被以下基团取代:卤素、苯基,
或者,
R1选自时,R2选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基,其中所述烷基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)芳香基、-N(C0-10烷基)杂环芳香基、芳基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R1选自时,R2选自H、C1-6烷基、C2-6烯基,其中所述烷基或烯基或炔基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、-OC0-6烷基、-S(O)mC0-6烷基、苯基,m为0、1或2,
其中,R8选自单键、C1-10亚烷基、C1-10亚烷基芳基、C(=O)N(C0-10烷基)(C1-10亚烷基)、-C(=O)N(C0-10烷基)(芳基)-,-芳基C(=O)N(C0-10烷基)-、-C1-10亚烷基C(=O)N(C0-10烷基)-,其中所述亚烷基、烷基、芳基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)芳香基、-N(C0-10烷基)杂环芳香基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R8选自单键、C1-6亚烷基、-N(C0-6烷基)C(=O)-、-N(C0-6烷基)C(=O)(C1-6亚烷基)、-N(C0-6烷基)C(=O)-、C1-6亚烷基N(C0-6烷基)C(=O)-、其中所述亚烷基、烷基、苯基上的任意碳原子可被一个或两个以上的以下基团取代:卤素、-OC0-6烷基,
R16、R17、R18、R19和R20独立的选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基,卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)R21、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、-N(C0-10烷基)芳香基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基、硅烷基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
其中,R21选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基,卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、-N(C0-10烷基)芳香基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基、硅烷基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R16、R17、R18、R19和R20独立的选自H、C1-6烷基、卤素、苯基、-CN、-OH、-S(O)2C0-3烷基、-C(=O)C0-3烷基、-N(C0-3烷基)C(=O)(C0-3烷基)、三甲基硅烷、三乙基硅烷、N杂环丁烷基,吡啶基、吡唑基、吡咯烷基、吡喃基、四氢吡喃基、噻吩、四氢呋喃基、吡嗪基、咪唑基、哌啶基,哌嗪基,吲哚基、吗啉基、高哌嗪基、噻吩基、呋喃基、噁唑基、-NHC(=O)R21,其中N原子上的H可任选的被C1-10烷基、C3-10环烷基、-CF3、叔丁氧羰基取代,
更优选的,R21选自C1-6直链或支链烷基、C3-10环烷基,卤素、-OC0-6烷基、苯基、N杂环丁烷基,吡啶基、吡唑基、吡咯烷基、吡喃基、四氢吡喃基、噻吩、四氢呋喃基、吡嗪基、咪唑基、哌啶基,哌嗪基,吲哚基、吗啉基、高哌嗪基、噻吩基、呋喃基、噁唑基,其中N原子上的H可任选的被C1-10烷基、C3-10环烷基、-CF3、叔丁氧羰基取代,
R10选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R10选自H、C1-6直链或支链烷基、苯基、吡啶基,
R11和R12独立的选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基、杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)杂环烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R11和R12独立的选自H、C1-6烷基、C3-10环烷基、苯基、N杂环丁烷基,吡啶基、吡唑基、吡咯烷基、吡喃基、四氢吡喃基、噻吩、四氢呋喃基、吡嗪基、咪唑基、哌啶基,哌嗪基,吲哚基、吗啉基、高哌嗪基、噻吩基、呋喃基、噁唑基,其中N原子上的H可任选的被C1-6烷基、C3-10环烷基、-CF3,叔丁氧羰基取代,优选的,所述的烷基被上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-OC0-6烷基、-S(O)mC0-6烷基、苯基、卤代苯基、苄基、对羟基苯基、吲哚基、-C(=O)OC0-6烷基、对甲酰胺基苯基、-C(=O)四氢吡咯、-C(=O)吗啉,m为0、1或2,
R13选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R13选自H、C1-6烷基、吡啶基、苯基、叔丁氧羰基,-C(=O)OC0-6烷基,
Y1和Y2选自N或C,
n选自1、2或3,
R14和R15独立的选自H、C1-10直链或支链烷基、C2-10直链或支链烯基、C2-10直链或支链炔基、C3-10环烷基、杂环烷基、-C(=O)C0-10烷基、-C(=O)杂环芳香基、-C(=O)芳香基、杂环芳香基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)杂环烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R14和R15独立的选自H、C1-6烷基、-C(=O)C0-6烷基、-C(=O)C0-6亚烷基苯基、-C(=O)吡啶基、-C(=O)吡嗪基、-C(=O)咪唑基、-C(=O)吡唑基、-C(=O)苯基,其中所述烷基、苯基、杂环芳香基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-OC0-6烷基、CF3,
R3、R4、R5和R6独立的选自H、C1-10烷基、C2-10烯基、C2-10炔基、C3-10环烷基,卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)R21、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、-N(C0-10烷基)芳香基、杂环烷基、芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基、硅烷基,其中所述烷基、芳基、杂环烷基、杂环芳香基、烯基或炔基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R3、R4、R5和R6独立的选自H、C1-6烷基、C3-10环烷基,卤素、-OC0-6烷基、-N(C0-6烷基)(C0-6烷基)、-N(C0-6烷基)C(=O)(C0-6烷基)、-N(C0-6烷基)C(=O)O(C0-6烷基)、-N(C0-6烷基)C(=O)N(C0-6烷基)、-C(=O)C0-6烷基、-C(=O)OC0-6烷基、-C(=O)N(C0-6烷基)(C0-6烷基)、苯基,
更优选的,R3选自-NH2,
更优选的,R4选自卤素,
更优选的,R5和R6独立的选自H、C1-6烷基,
R7选自H、C1-10烷基、C3-10环烷基、-OC0-10烷基、C(=O)C0-10烷基,其中所述烷基上的任意碳原子可被一个或两个以上的以下基团任意取代:卤素、-CN、-OC0-10烷基、-S(O)mC0-10烷基、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)C(=O)(C0-10烷基)、-N(C0-10烷基)C(=O)O(C0-10烷基)、-N(C0-10烷基)C(=O)N(C0-10烷基)、-C(=O)C0-10烷基、-C(=O)OC0-10烷基、-C(=O)N(C0-10烷基)(C0-10烷基)、-杂环烷基、-N(C0-10烷基)杂环烷基、-N(C0-10烷基)杂环芳香基、杂环烷基、芳基、-C1-10烷基芳基、-C1-10烷基杂环芳香基、-N杂环芳香基、-S杂环芳香基或-O杂环芳香基,m为0、1或2,
优选的,R7选自H、C1-6烷基,
更优选的,R7选自H。
在本发明的具体实施方式中提供式(Ⅱ)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅱ-1)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅱ-2)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
在本发明的具体实施方式中提供式(Ⅲ)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅲ-1)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅲ-2)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅲ-3)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
在本发明的具体实施方式中提供式(Ⅳ)的化合物,及其药学上可接受的盐、立体异构体、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅳ-1)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
其中,R22、R23、R24、R25和R26独立的选自卤素、-NH2、-OH、C1-10烷基、-CF3,m为0、1、2。
在本发明的具体实施方式中提供式(Ⅴ)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅴ-1)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅴ-2)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅴ-3)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
在本发明的具体实施方式中提供式(Ⅵ)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
优选的,在本发明的具体实施方式中提供式(Ⅵ-1)的化合物,及其药学上可接受的盐、立体异构体、醚、酯、前药和溶剂化物,
其中,R22、R23、R24、R25和R26独立的选自卤素、-NH2、-OH、C1-10烷基、-CF3,m为0、1、2。
在本发明更具体实施方式中,提供如下的具体化合物:
本发明所述的式(I)的化合物可以采用如下的反应路线进行:
(路线1)4-取代吡唑类化合物的合成:
化合物1(1eq.)加入反应溶剂二氯甲烷中,化合物2(1.2eq.)分批加至溶液中。所得反应液在r.t.下反应8h后,二氯甲烷DCM萃取后使用硅胶柱层析分离,得到中间体3。中间体3(1eq.),对甲苯磺酰肼(TsNHNH2,2eq.)和四丁基溴化铵(TBAB,1eq.)分批缓慢加入NaOH(3eq.)的水溶液中,边加边搅拌。所得的混合液在95℃下搅拌12h。反应液降至室温,并使用2N的盐酸调pH至4~5。所得混合液使用等体积乙酸乙酯萃取三次。有机相使用水和盐水洗之后,使用无水硫酸钠进行干燥。过滤出去硫酸钠后,有机相使用旋转蒸发仪去除。所得粗品使用硅胶柱层析的方法进行分离纯化,得到中间体4。中间体4(1eq.),N-碘代丁二酰亚胺NIS(1.1eq.)溶解于二氯甲烷在r.t.下反应12h,得到中间体5。中间体5(1.0eq.),邻苯二甲酸二庚酯DHP(2.0eq.)及PPST(0.2eq.)溶解于二氯甲烷,在r.t.下反应12h后,中性氧化铝层析柱分离得到中间体6。中间体6(1.0eq.),烯基频那硼酸酯(1.2eq.),Pd(PPh3)4(0.05eq.)以及K2CO3(2.0eq.)溶解于二甲醚DME和水的混合溶剂,在100℃反应12h后,中性氧化铝层析柱分离得到中间体7。中间体7溶解于乙醇,并加入2NHCl的乙醇溶液,乙酸乙酯萃取并加入饱和碳酸氢钠,有机相旋干得到中间体8直接用于下一步的反应。中间体8溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,减压旋走溶剂,粗品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到中间体9。中间体9溶解于乙醇,并加入还原Fe粉以及氯化铵的水溶液,在r.t.下反应12h后硅胶柱层析分离得到取代吡唑类化合物。
(路线2)5-取代吡唑类化合物的合成:
中间体10使用干燥的四氢呋喃THF溶解,然后在冰浴下滴入酮(1.1eq.)和LiHMDS(1.5eq.)的反应溶液中。所得反应液在r.t.下搅拌1h后,加水淬灭。使用二氯甲烷萃取,有机相使用无水硫酸镁干燥。干燥剂被过滤后,有机相拌硅胶,使用硅胶层析柱分离纯化,得到中间体11。中间体11溶解于甲醇,NH2NH2·H2O(3.0eq.)滴加到反应液中,在r.t.下反应12h后,旋干得到粗产品中间体12直接用于下一步反应。中间体12溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干得到粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到中间体13。中间体13溶解于乙醇,并加入还原Fe粉以及氯化铵的水溶液,在r.t.下反应12h后硅胶柱层析分离得到5-取代吡唑类化合物。
(路线3)5-芳基取代吡唑类化合物衍生物的合成:
将中间体12(1eq),4-甲基苯磺酸吡啶(PPTS,0.1eq)溶于二氯甲烷,再加入3,4-二氢-2H-吡喃(DHP,3eq),室温反应24h,反应结束后减压旋走有机相,粗产物用中性三氧化二铝进行柱层析分离得到中间体15.
将中间体15(1eq)溶于乙二醇二甲醚和水的混合液(DME:H2O=4:1)中,加入K2CO3(2.5eq),Pd(PPh3)4(0.1eq),芳基硼酸化合物(1.2eq)。氮气保护后加热至100℃反应24h,反应结束后减压旋走有机溶剂,然后用乙酸乙酯萃取两次,有机相干燥后用硅胶柱层析纯化得到中间体16。将中间体16溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干有机相,粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到吡唑环类化合物的芳香环衍生物。
将中间体15(1eq),胺基化合物(2eq)溶于甲苯,再加入Pd2(dba)3(0.05eq),1,1'-联萘-2,2'-双二苯膦(BINAP,0.1eq),NaOtBu(2.5eq)。反应瓶用氮气置换保护后,加热至105℃反应24h。反应结束后用乙酸乙酯萃取,有机相分别用水和盐水洗一次,干燥后用硅胶柱层析纯化得到中间体17。将中间体17溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干有机相,粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到吡唑环类化合物的胺基衍生物。
(路线4)双N杂环取代吡唑类化合物的合成:
将化合物18(1eq)溶于无水甲苯,加入二硫化碳(1.6eq),碘甲烷(3.5eq),将反应器冰浴,慢慢加入NaH(2.2eq),加完后再慢慢滴入N,N-二甲基乙酰胺(2.2eq),加完后将反应器提升至室温反应两天,反应结束后,加水淬灭反应,有机相分别用水和盐水各洗一次,干燥后硅胶柱层析纯化得到化合物19。将化合物19溶于乙醇,加入胺类化合物R1(2.2eq),搅拌下加热回流24h,反应结束后,直接用硅胶柱层析纯化得到化合物20。将化合物20溶解于无水乙醇中,加入98%水合肼(2eq),加热回流12h,反应结束后,直接用硅胶柱层析纯化得到胺基取代吡唑类化合物。
(路线5)对酰胺芳基取代吡唑骨架类化合物的合成
中间体40(1.0eq.),DHP(3.0eq.)及PPST(0.2eq.)溶解于二氯甲烷,在r.t.下反应12h后,中性氧化铝层析柱分离得到中间体41。中间体41(1.0eq.),酰胺(1.2eq.),Pd(OAc)2(0.02eq),Xantphos(0.03eq.)以及Cs2CO3(1.4eq.)溶解于1,4-二氧六环,在100℃反应12h后,中性氧化铝层析柱分离得到中间体42。中间体42溶解于乙醇,并加入2NHCl的乙醇溶液,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到对酰胺芳基取代吡唑骨架类化合物。
(路线6)吡唑酰胺类化合物的合成
将化合物43(1eq)滴加到EtONa(2.3eq)室温搅拌1h,然后慢慢滴入草酸二乙酯,加热回流4h,反应结束后冷却到室温,然后加入冰醋酸(4eq),产生大量白色固体,将产物过滤,然后分别用少量水,乙醇,乙醚冲洗得到产物44。将中间体44溶解到到乙酸中,然后冰浴下慢慢滴入水合肼(1.2eq),室温下反应过夜,反应结束后将产物过滤,将反应产物在乙醇里进行重结晶,得到中间体45。将中间体45溶解于无水二氯甲烷中,-78℃加入BBr3(6eq),1h后将反应升至室温,反应过夜,反应结束后,慢慢加水淬灭反应,有机相用旋转蒸发仪除去,将反应液pH值调至5,用乙酸乙酯将产物萃取出来,干燥后减压旋走有机溶剂即得到中间体46。将中间体46,EDCI(1.2eq),HOBt(1.2eq)加入到无水DMF中,搅拌半小时后再加入相应的胺类化合物R,反应12h,反应结束后加入乙酸乙酯,有机相用饱和氯化铵溶液洗三次,饱和氯化钠溶液洗一次,无水硫酸镁干燥后用硅胶柱层析春华,的到最后产物吡唑酰胺类化合物。
(路线7)5-取代氨基吡唑类化合物的合成
将化合物47(1.0eq.),碘甲烷(3.0eq.),碳酸钾(3.0eq.)溶于一定量丙酮溶液,40℃下搅拌反应12h,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体48。48(1.0eq.)溶于超干甲苯中,加入乙腈(3.0eq.),然后加入氢化钠(3.0eq.),加缓冲气球,加热到90℃反应3h。旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体49。49(1.0eq.)和一水合肼(1.2eq.)一起溶于乙醇,再加入冰醋酸(6.0eq.),50℃加热反应3h时后,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体50。50与不同类型羧酸按照一比一当量加入DMF溶剂,加入HATU(1.5eq.)和DIPEA(1.5eq.),70℃下反应12h,乙酸乙酯萃取粗品干燥后,硅胶柱层析纯化得到中间体51。51或50(1eq.)溶于超干DCM中,0℃下加入三溴化硼(8eq.),常温下搅拌反应12h,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到终产物5-取代氨基吡唑类化合物。
本发明所述的药学上可接受的盐中包括酸加成盐和碱加成盐。
所述的酸加成盐包括但是不限于来自无机酸诸如盐酸、硝酸、磷酸、硫酸、氢溴酸、氢碘酸和膦酸的盐,以及来自有机酸如脂肪族单羧酸和二羧酸、苯基取代的链烷酸、羟基链烷酸、链烷二酸、芳香酸和脂肪族和芳香族磺酸的盐。因此,这些盐包括但是不限于硫酸盐,焦硫酸盐,硫酸氢盐,亚硫酸盐,亚硫酸氢盐,硝酸盐,磷酸,磷酸一氢盐,磷酸二氢盐,偏磷酸盐,焦磷酸盐,盐酸盐,氢溴酸盐,碘酸盐,乙酸盐,丙酸盐,辛酸盐,异丁酸盐,乙二酸盐,丙二酸盐,琥珀酸盐,辛二酸,癸二酸盐,富马酸盐,马来酸盐,苦杏仁酸盐,苯甲酸盐,氯代苯甲酸盐,甲基苯甲酸盐,二硝基苯甲酸盐,酞酸盐,苯磺酸盐,甲苯磺酸盐,苯基乙酸盐,柠檬酸盐,乳酸盐,马来酸盐,酒石酸和甲磺酸盐,还包含氨基酸的盐如精氨酸盐,葡糖酸盐,半乳糖醛酸盐等。酸加成盐可以通过以常规方式使游离碱与足够量的所需酸接触形成盐的方式制备。可通过使盐与碱接触重新生成游离碱形式,并且以常规方式分离该游离碱。
所述的碱加成盐与金属或者胺形成,诸如碱金属和碱土金属的氢氧化物,或者与有机胺形成。用作阳离子的金属的例子包括但是不限于钠、钾、镁、和钙。适当的胺的例子包括但是不限于N,N′-二苄基乙二胺,氯普鲁卡因,胆碱,二乙醇胺,乙二胺(乙烷-1,2-二胺),N-甲基葡糖胺和普鲁卡因。碱加成盐可通过以常规方式使游离酸与足够量的所需碱接触形成盐的方式制备。可通过使盐与酸接触重新生成游离酸形式,并且以常规方式分离游离酸。
本发明所述的立体异构体包括对映体、非对映体和几何异构体的形式存在。本发明的一些化合物具有环烷基,其可在超过一个碳原子上被取代,在这种情况下,其所有的几何形式,包括顺式和反式,及其混合物,都处在本发明的范围内。
本发明所述的溶剂化物是指本发明的化合物与一种或多种溶剂分子的物理结合。该物理结合包括各种程度的离子和共价键合,包括氢键合。在某些情况下,溶剂化物可被分离出来,例如当一个或多个溶剂分子掺入到结晶固体的晶格中。“溶剂化物”包括溶液相的和可分离的溶剂化物。代表性的溶剂化物包括乙醇化物、甲醇化物等。“水合物”是其中一个或多个溶剂分子为H2O的溶剂化物。
本发明所述的前药指适于对患者给药的无过分毒性、刺激性和变态反应等的并且对其应用目的有效的式Ⅰ化合物形式,包括缩醛、酯和两性离子形式。前药在体内转化(例如通过在血液中水解)得到上式的母体化合物。
本发明另外提供了药物组合物,其包含本发明的化合物(例如式I化合物及其药学上可接受的盐、立体异构体、酯、前药和溶剂化物),以及可药用的载体、稀释剂或赋形剂。优选地,药物组合物包含治疗有效量的本发明的化合物。
本发明的化合物可以配制为以下形式的药物组合物:糖浆剂,酏剂,悬浮剂,粉剂,颗粒剂,片剂,胶囊,锭剂,水溶液,霜剂,膏剂,洗液剂,凝胶剂,乳剂等。
药物制剂优选为单位剂型。在这种形式中,该制剂被再分成包含适当的量的活性组分的单位剂量。单位剂型可以是包装好的制剂,该包装含有离散的量的制剂,诸如包装在小瓶或者安瓿中的片剂、胶囊和粉剂。另外,单位剂型可以是胶囊,片剂或者其可以是在包装形式中的适当数目的任何这些剂型。
单位剂量制剂中活性组分的量可从0.001毫克到1000毫克之间改变或调整,根据活性组分的具体应用和效力而定。如果需要,组合物还可包含其它适合的治疗剂。
可药用载体部分地根据给用的具体组合物而定,并根据组合物的具体给药方法而定。因此,本发明的药物组合物存在各种适当的制剂。
本发明的化合物,单独或与其它适当的组分结合,被制成气雾剂(即,它们可被“雾化”)以经由吸入被给药。气雾剂可被置于可接受的被加压的发射剂诸如二氯二氟己烷、丙烷、氮气等中。
适于非肠胃给药诸如例如通过静脉内、肌内、皮内和皮下途径给药的制剂包括含水和非水的等渗无菌注射液,其可包含抗氧化剂,缓冲剂,抑菌剂,和使制剂与接受者的血液等渗的溶质,以及含水和非水的无菌悬浮剂,其可包含助悬剂,增溶剂,增稠剂,稳定剂和防腐剂。在本发明的实践中,组合物可通过例如静脉内输注,经口,局部,腹膜内,膀胱内和鞘内给药。化合物的制剂可存在于单位剂量或者多剂量密封容器诸如安瓿和小瓶中。注射用溶液液和悬浮液可从先前所述类型的无菌粉剂、颗粒和片剂制备。
在本发明的环境下,对对象剂量给用应当足够随着时间在对象体内产生有益的治疗学应答。剂量通过所用的具体化合物的效力和对象的病况、以及待治疗对象的体重或者体表面积而定。剂量的大小将根据在具体对象中伴随具体化合物给药产生的任何不利副作用的存在、性质和程度而定。在正被治疗的病症的治疗或者预防中确定待给药的化合物的有效量中,医师可以评价诸如化合物的循环血浆水平、化合物毒性和/或疾病进程等因素而定。
本发明还提供了式(I)的化合物及其药学上可接受的盐、立体异构体、酯、前药和溶剂化物在预防和/或治疗癌症中的应用。
本发明还提供了式(I)的化合物及其药学上可接受的盐、立体异构体、酯、前药和溶剂化物在癌症免疫疗法中的应用。
本发明还提供了式(I)的化合物及其药学上可接受的盐、立体异构体、酯、前药和溶剂化物在制备预防和/或治疗癌症的药物中的应用。
本发明所述的癌症包括淋巴瘤,母细胞瘤,髓母细胞瘤,视网膜母细胞瘤,肉瘤,脂肪肉瘤,滑膜细胞肉瘤,神经内分泌肿瘤,类癌肿瘤,胃泌素瘤,胰岛细胞癌,间皮瘤,神经鞘瘤,听神经瘤,脑膜瘤,腺癌,黑素瘤,白血病或淋巴样恶性肿瘤,鳞状细胞癌,上皮鳞状细胞癌,肺癌,小细胞肺癌,非小细胞肺癌,腺癌肺癌,肺鳞癌,腹膜癌,肝细胞癌,胃癌,肠癌,胰腺癌,成胶质细胞瘤,子宫颈癌,卵巢癌,肝癌,膀胱癌,肝癌,乳腺癌,转移性乳腺癌,结肠癌,直肠癌,结肠直肠癌,子宫癌,唾液腺癌,肾癌,前列腺癌,外阴癌,甲状腺癌,肝癌,肛门癌,阴茎癌,梅克尔细胞癌,食管癌,胆道肿瘤,头颈部癌和血液恶性肿瘤。
本发明中所述的术语C0-10烷基,C0烷基是指H,因此,C0-10烷基包括H、C1烷基、C2烷基、C3烷基、C4烷基、C5烷基、C6烷基、C7烷基、C8烷基、C9烷基、C10烷基。
本发明中所述的术语C1-10亚烷基,包括C1亚烷基、C2亚烷基、C3亚烷基、C4亚烷基、C5亚烷基、C6亚烷基、C7亚烷基、C8亚烷基、C9亚烷基、C10亚烷基。
本发明中所述的术语C3-10环烷基,包括C3环烷基、C4环烷基、C5环烷基、C6环烷基、C7环烷基、C8环烷基、C9环烷基、C10环烷基。
本发明中所述的术语C1-6烷基,包括HC1烷基、C2烷基、C3烷基、C4烷基、C5烷基、C6烷基。
本发明中所述的术语C1-6直链烷基,包括甲基、乙基、C3直链烷基、C4直链烷基、C5直链烷基、C6直链烷基。
本发明中所述的术语C3-6环烷基,包括C3环烷基、C4环烷基、C5环烷基、C6环烷基。
本发明所述的术语卤素,包括氟、氯、溴、碘。
本发明所述的术语杂环烷基是指含3-10个环原子,优选5-10个环原子的非芳香的饱和单环或多环环系,其中的一个或多个环原子不是碳原子,而是例如氮、氧或硫原子。优选的杂环烷基含有5-6个环原子。杂环烷基前的前缀氮杂、氧杂或硫杂分别是指至少有一个氮、氧或硫原子作为环原子。代表性的单环杂环烷基包括哌啶基、吡咯烷基、哌嗪基、吗啉基、硫代吗啉基、噻唑烷基、1,3-二氧戊环基、1,4-二氧杂环己烷基、四氢呋喃基、四氢噻吩基、四氢噻喃基等。
本发明所述的术语杂环芳香基是指含5-14个环原子,优选5-10个环原子的芳香单环或多环环系,其中的一个或多个环原子不是碳原子,而是例如氮、氧或硫原子。优选的杂环芳香基含有5-6个环原子。代表性的杂环芳香基包括吡嗪基、呋喃基、噻吩基、吡啶基、嘧啶基、异噁唑基、异噻唑基、噁唑基、噻唑基、吡唑基、呋咱基、吡咯基、吡唑基、三唑基、1,2,4-硫杂二唑基、吡嗪基、哒嗪基、喹喔啉基、2,3-二氮杂萘基、咪唑并[1,2-a]吡啶、咪唑并[2,1-b]噻唑基、苯并呋咱基、吲哚基、氮杂吲哚基、苯并咪唑基、苯并噻吩基、喹啉基、咪唑基、噻吩并吡啶基、喹唑啉基、噻吩并嘧啶基、吡咯并吡啶基、咪唑并吡啶基、异喹啉基、苯并氮杂吲哚基、1,2,4-三嗪基、苯并噻唑基等。
本发明所述的术语Me代表甲基的缩写。
本发明所述的术语Ph代表苯基的缩写。
本发明所述的术语Boc代表叔丁氧羰基的缩写。
本发明所述的术语“单位剂型”指适合作为人受试者和其它哺乳动物的单一剂量的物理上离散的单位,每个单位包含与需要的药物载体结合的经计算可在治疗期间的过程中产生期望的预防或治疗效果的预定量的活性物质。
本发明所述的术语“辅料”含义是该成分没有生物活性或其他不良活性的杂质,例如该成分可以纳入公开的药物制剂并给与患者,但不引起显著的不良生物效果或以有害的方式和该制剂中包含的其他成分产生相互作用。
本发明所述的术语“治疗”包括抑制、延迟、缓和、减弱、限制、减轻或消退疾病、障碍、病症或状态,其发生和/或进程,和/或其症状。
本发明所述的术语“预防”包括减小以下风险:患有、感染或经历疾病、障碍、病症或状态,其发生和/或进程,和/或其症状。
本发明所述的术语“包含”表示"开放"或"包含性"用语,使得它们包括列举的要素,而且还允许包括额外的、未提及的要素。
本发明所述的术语“约”通常意指所述值的+/-5%,更通常指所述值的+/-4%,更通常指所述值的+/-3%,更通常指所述值的+/-2%,更通常指所述值的+/-1%,更通常指所述值的+/-0.5%。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1 4-取代吡唑类化合物(BRM2-1~3)的合成:
化合物1(1eq.)加入反应溶剂二氯甲烷中,化合物2(1.2eq.)分批加至溶液中。所得反应液在r.t.下反应8h后,二氯甲烷萃取后使用硅胶柱层析分离,得到中间体3。中间体3(1eq.),对甲苯磺酰肼(2eq.)和四丁基溴化铵(TBAB,1eq.)分批缓慢加入NaOH(3eq.)的水溶液中,边加边搅拌。所得的混合液在95℃下搅拌12h。反应液降至室温,并使用2N的盐酸调pH至4~5。所得混合液使用等体积乙酸乙酯萃取三次。有机相使用水和盐水洗之后,使用无水硫酸钠进行干燥。过滤出去硫酸钠后,有机相使用旋转蒸发仪去除。所得粗品使用硅胶柱层析的方法进行分离纯化,得到中间体4。中间体4(1eq.),NIS(1.1eq.)溶解于二氯甲烷在r.t.下反应12h,得到中间体5。中间体5(1.0eq.),DHP(2.0eq.)及PPST(0.2eq.)溶解于二氯甲烷,在r.t.下反应12h后,中性氧化铝层析柱分离得到中间体6。中间体6(1.0eq.),烯基频那硼酸酯(1.2eq.),Pd(PPh3)4(0.05eq.)以及K2CO3(2.0eq.)溶解于DME和水的混合溶剂,在100℃反应12h后,中性氧化铝层析柱分离得到中间体7。中间体7溶解于乙醇,并加入2NHCl的乙醇溶液,乙酸乙酯萃取并加入饱和碳酸氢钠,有机相旋干得到中间体8直接用于下一步的反应。中间体8溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,减压旋走溶剂,粗品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到中间体9。中间体9溶解于乙醇,并加入还原Fe粉以及氯化铵的水溶液,在r.t.下反应12h后硅胶柱层析分离得到取代吡唑类化合物BRM2-1~3。
实施例2 5-取代吡唑类化合物(BRM2-4~20)的合成:
中间体10使用干燥的四氢呋喃溶解,然后在冰浴下滴入酮(1.1eq.)和LiHMDS(1.5eq.)的反应溶液中。所得反应液在r.t.下搅拌1h后,加水淬灭。使用二氯甲烷萃取,有机相使用无水硫酸镁干燥。干燥剂被过滤后,有机相拌硅胶,使用硅胶层析柱分离纯化,得到中间体11。中间体11溶解于甲醇,NH2NH2·H2O(3.0eq.)滴加到反应液中,在r.t.下反应12h后,旋干得到粗产品中间体12直接用于下一步反应。中间体12溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干得到粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到中间体13。中间体13溶解于乙醇,并加入还原Fe粉以及氯化铵的水溶液,在r.t.下反应12h后硅胶柱层析分离得到化合物BRM2-4~20。
实施例3 5-芳基取代吡唑类化合物衍生物(BRM2-21~39)的合成
将中间体12(1eq),4-甲基苯磺酸吡啶(PPTS,0.1eq)溶于二氯甲烷,再加入3,4-二氢-2H-吡喃(DHP,3eq),室温反应24h,反应结束后减压旋走有机相,粗产物用中性三氧化二铝进行柱层析分离得到中间体15.
吡唑环类化合物的芳香环衍生物合成方法:将中间体15(1eq)溶于乙二醇二甲醚和水的混合液(DME:H2O=4:1)中,加入K2CO3(2.5eq),Pd(PPh3)4(0.1eq),芳基硼酸化合物(1.2eq)。氮气保护后加热至100℃反应24h,反应结束后减压旋走有机溶剂,然后用乙酸乙酯萃取两次,有机相干燥后用硅胶柱层析纯化得到中间体16。将中间体16溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干有机相,粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到化合物BRM2-21~30,35,37。
吡唑环类化合物的胺基衍生物合成方法:将中间体15(1eq),胺基化合物(2eq)溶于甲苯,再加入Pd2(dba)3(0.05eq),1,1'-联萘-2,2'-双二苯膦(BINAP,0.1eq),NaOtBu(2.5eq)。反应瓶用氮气置换保护后,加热至105℃反应24h。反应结束后用乙酸乙酯萃取,有机相分别用水和盐水洗一次,干燥后用硅胶柱层析纯化得到中间体17。将中间体17溶解于二氯甲烷,-78℃加入BBr3(10eq.),然后将反应升温至室温,反应24h,反应结束后,旋干有机相,粗产品用乙酸乙酯溶解后,水洗一次,盐水洗一次,有机相干燥后硅胶柱层析纯化得到化合物BRM2-31~34,36,38~39。
实施例4双N杂环取代吡唑类化合物(BRM2-40~42)的合成
将化合物18(1eq)溶于无水甲苯,加入二硫化碳(1.6eq),碘甲烷(3.5eq),将反应器冰浴,慢慢加入NaH(2.2eq),加完后再慢慢滴入N,N-二甲基乙酰胺(2.2eq),加完后将反应器提升至室温反应两天,反应结束后,加水淬灭反应,有机相分别用水和盐水各洗一次,干燥后硅胶柱层析纯化得到化合物19。将化合物19溶于乙醇,加入胺类化合物R1(2.2eq),搅拌下加热回流24h,反应结束后,直接用硅胶柱层析纯化得到化合物20。将化合物20溶解于无水乙醇中,加入98%水合肼(2eq),加热回流12h,反应结束后,直接用硅胶柱层析纯化得到胺基取代吡唑类化合物BRM2-40~42.
实施例5对酰胺芳基取代吡唑骨架类化合物(BRM2-96~128)的合成
中间体40(1.0eq.),DHP(3.0eq.)及PPST(0.2eq.)溶解于二氯甲烷,在r.t.下反应12h后,中性氧化铝层析柱分离得到中间体41。中间体41(1.0eq.),酰胺(1.2eq.),Pd(OAc)2(0.02eq),Xantphos(0.03eq.)以及Cs2CO3(1.4eq.)溶解于1,4-二氧六环,在100℃反应12h后,中性氧化铝层析柱分离得到中间体42。中间体42溶解于乙醇,并加入2NHCl的乙醇溶液,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到化合物BRM2-96~128。
实施例6吡唑酰胺类化合物(BRM2-129~159)的合成
将化合物43(1eq)滴加到EtONa(2.3eq)室温搅拌1h,然后慢慢滴入草酸二乙酯,加热回流4h,反应结束后冷却到室温,然后加入冰醋酸(4eq),产生大量白色固体,将产物过滤,然后分别用少量水,乙醇,乙醚冲洗得到产物44。将中间体44溶解到到乙酸中,然后冰浴下慢慢滴入水合肼(1.2eq),室温下反应过夜,反应结束后将产物过滤,将反应产物在乙醇里进行重结晶,得到中间体45。将中间体45溶解于无水二氯甲烷中,-78℃加入BBr3(6eq),1h后将反应升至室温,反应过夜,反应结束后,慢慢加水淬灭反应,有机相用旋转蒸发仪除去,将反应液pH值调至5,用乙酸乙酯将产物萃取出来,干燥后减压旋走有机溶剂即得到中间体46。将中间体46,EDCI(1.2eq),HOBt(1.2eq)加入到无水DMF中,搅拌半小时后再加入相应的胺类化合物R,反应12h,反应结束后加入乙酸乙酯,有机相用饱和氯化铵溶液洗三次,饱和氯化钠溶液洗一次,无水硫酸镁干燥后用硅胶柱层析春华,的到最后产物BRM2-129~159.
实施例7 5-取代氨基吡唑类化合物(BRM2-160~174)的合成
将化合物47(1.0eq.),碘甲烷(3.0eq.),碳酸钾(3.0eq.)溶于一定量丙酮溶液,40℃下搅拌反应12h,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体48。48(1.0eq.)溶于超干甲苯中,加入乙腈(3.0eq.),然后加入氢化钠(3.0eq.),加缓冲气球,加热到90℃反应3h。旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体49。49(1.0eq.)和一水合肼(1.2eq.)一起溶于乙醇,再加入冰醋酸(6.0eq.),50℃加热反应3h时后,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到中间体50。50与不同类型羧酸按照一比一当量加入DMF溶剂,加入HATU(1.5eq.)和DIPEA(1.5eq.),70℃下反应12h,乙酸乙酯萃取粗品干燥后,硅胶柱层析纯化得到中间体51。51或50(1eq.)溶于超干DCM中,0℃下加入三溴化硼(8eq.),常温下搅拌反应12h,旋干溶剂,乙酸乙酯萃取并加入饱和碳酸氢钠,粗品干燥后,硅胶柱层析纯化得到终产物BRM2-160-174。
实施例8实施例1-7制备得到化合物的谱图数据
在本实施例中,按照前面所描述的一般合成方法制备得到的化合物,相应的合成鉴定谱图数据如下:
BRM2-1:1HNMR(400MHz,CDCl3)δ6.97–6.82(m,1H),6.48(dd,J=17.9,11.6Hz,1H),6.31(dd,J=8.6,4.0Hz,1H),5.22(dd,J=38.2,14.7Hz,2H),2.74(t,J=7.6Hz,2H),1.73(dd,J=15.1,7.5Hz,2H),1.03(t,J=7.3Hz,3H).质谱(ESI,m/z):C14H16FN3O,[M+H]+:262.13.
BRM2-2:1HNMR(400MHz,CDCl3)δ7.34(dt,J=15.2,7.6Hz,4H),7.25(t,J=6.8Hz,1H),6.96(t,J=9.7Hz,1H),6.86(d,J=16.6Hz,1H),6.65(d,J=16.6Hz,1H),6.34(d,J=5.2Hz,1H),2.88(t,J=7.6Hz,2H),1.88-1.80(m,2H),1.08(t,J=7.3Hz,3H).质谱(ESI,m/z):C20H20FN3O,[M+H]+:338.16.
BRM2-3:1HNMR(400MHz,CDCl3)δ6.97–6.82(m,1H),6.27(dd,J=8.8,4.1Hz,1H),6.07(d,J=16.1Hz,1H),5.78–5.62(m,1H),2.68–2.48(m,2H),2.06(q,J=7.1Hz,2H),1.70–1.51(m,2H),1.37(dd,J=14.6,7.3Hz,2H),0.93(t,J=7.3Hz,3H),0.87(t,J=7.3Hz,4H).质谱(ESI,m/z):C17H20FN3O,[M+H]+:304.17.
BRM2-4:1HNMR(400MHz,MeOD)δ7.71(d,J=6.8Hz,2H),7.59(d,J=6.8Hz,2H),7.01(s,1H),6.82(t,J=8.9Hz,1H),6.20(s,1H).质谱(ESI,m/z):C15H10BrFN2O,[M+H]+:333.00.
BRM2-5:1HNMR(400MHz,MeOD)δ7.69(d,J=8.2Hz,2H),7.56–7.41(m,3H),7.05(s,1H),6.97–6.85(m,2H),1.35(s,9H).质谱(ESI,m/z):C19H19FN2O,[M+H]+:311.15.
BRM2-6:1HNMR(400MHz,MeOD)δ7.67(d,J=7.9Hz,2H),7.50–7.39(m,1H),7.28(d,J=8.0Hz,2H),7.02(s,1H),7.00–6.77(m,2H),2.67(q,J=7.6Hz,2H),1.25(t,J=7.6Hz,3H).质谱(ESI,m/z):C17H15FN2O,[M+H]+:283.12.
BRM2-7:1HNMR(400MHz,MeOD)δ7.43(d,J=8.3Hz,2H),7.30(s,3H),6.90(d,J=5.7Hz,2H),6.83(s,1H),2.42(s,3H).质谱(ESI,m/z):C16H13FN2O,[M+H]+:269.10.
BRM2-8:1HNMR(400MHz,MeOD)δ7.66–7.48(m,2H),7.48–7.38(m,1H),7.32(t,J=7.6Hz,1H),7.18(d,J=7.5Hz,1H),7.04(s,1H),6.89(d,J=5.5Hz,2H),2.39(s,3H).质谱(ESI,m/z):C16H12FN2O,[M+H]+:269.10.
BRM2-9:1HNMR(400MHz,MeOD)δ7.42(d,J=10.3Hz,1H),7.26(s,1H),7.15(dd,J=26.4,7.6Hz,2H),6.90(d,J=5.3Hz,2H),6.82(s,1H),2.35(d,J=14.3Hz,6H).质谱(ESI,m/z):C17H15FN2O,[M+H]+:283.12.
BRM2-10:1HNMR(400MHz,MeOD)δ7.44(d,J=9.7Hz,1H),7.38(s,2H),7.03(d,J=4.8Hz,2H),6.89(d,J=4.1Hz,2H),2.36(s,6H).质谱(ESI,m/z):C17H15FN2O,[M+H]+:283.12.
BRM2-11:1HNMR(400MHz,CDCl3)δ7.35–7.30(m,1H),7.26(s,2H),7.10(s,1H),7.05–6.93(m,2H),6.87(s,1H),2.42(s,6H).质谱(ESI,m/z):C17H15FN2O,[M+H]+:283.12.
BRM2-12:1HNMR(400MHz,DMSO)δ13.44(d,J=188.0Hz,1H),10.52(s,1H),7.93(s,1H),7.64(s,1H),7.38(d,J=36.3Hz,4H),7.04(t,J=8.3Hz,1H),6.97(d,J=4.8Hz,1H).质谱(ESI,m/z):C15H10F2N2O,[M+H]+:273.08.
BRM2-13:1HNMR(400MHz,CDCl3)δ7.46(d,J=7.8Hz,2H),7.07(d,J=7.9Hz,2H),6.93–6.85(m,1H),6.61(s,1H),6.37(d,J=4.5Hz,1H),3.12-3.04(m,2H),3.02-2.94(m,2H).质谱(ESI,m/z):C15H10ClFN2O,[M+H]+:289.05.
BRM2-14:1HNMR(400MHz,MeOD)δ12.62(s,1H),7.68-7.66(m,2H),7.45(m,1H),7.35-7.30(m,2H),7.05-6.95(m,2H),6.81(m,1H).质谱(ESI,m/z):C15H10BrFN2O,[M+H]+:333.00.
BRM2-15:1HNMR(400MHz,MeOD)δ7.47(d,J=6.6Hz,1H),7.35–7.19(m,3H),6.90–6.74(m,2H),6.24(dd,J=8.8,4.2Hz,1H),2.44(s,3H).质谱(ESI,m/z):C15H11BrFN3O,[M+H]+:348.01.
BRM2-16:1HNMR(400MHz,MeOD)δ7.42(d,J=7.5Hz,1H),7.34(d,J=4.0Hz,2H),7.29–7.19(m,1H),6.95-6.81(m,2H),6.22(dd,J=8.8,4.2Hz,1H),2.80(q,J=7.6Hz,2H),1.17(t,J=7.5Hz,3H).质谱(ESI,m/z):C16H13BrFN3O,[M+H]+:362.02.
BRM2-17:1HNMR(400MHz,CDCl3)δ7.50-7.42(m,2H),7.35–7.24(m,2H),6.93-6.86(m,2H),6.36(s,1H),3.32–3.02(m,1H),1.23(d,J=6.5Hz,6H).质谱(ESI,m/z):C15H12BrN3O,[M+H]+:330.02.
BRM2-18:1HNMR(400MHz,DMSO)δ13.44(d,J=188.0Hz,1H),10.52(s,1H),7.93(s,1H),7.64(s,1H),7.38(d,J=36.3Hz,4H),7.04(t,J=8.3Hz,1H),6.97(d,J=4.8Hz,1H).质谱(ESI,m/z):C16H14FN3O,[M+H]+:284.11.
BRM2-19:1HNMR(400MHz,Acetone)δ12.90(s,1H),10.72(s,1H),7.78(dd,J=5.9,3.4Hz,1H),7.62(ddd,J=12.6,7.4,2.8Hz,2H),7.55–7.47(m,2H),7.32(s,1H),7.06–6.93(m,2H).质谱(ESI,m/z):C17H16FN3O,[M+H]+:298.13.
BRM2-20:1HNMR(400MHz,CDCl3)δ7.85(s,1H),7.61(d,J=7.7Hz,1H),7.48(d,J=7.9Hz,1H),7.29(dd,J=13.4,6.5Hz,2H),6.90(d,J=5.6Hz,2H),6.83(s,1H).质谱(ESI,m/z):C18H18FN3O,[M+H]+:312.14.
BRM2-21:1HNMR(400MHz,MeOD)δ7.86(d,J=7.0Hz,2H),7.68(dd,J=19.1,7.3Hz,4H),7.45(t,J=6.8Hz,2H),7.35(d,J=6.8Hz,1H),7.07(s,1H),6.82(t,J=9.5Hz,1H),6.22(d,J=4.9Hz,1H).质谱(ESI,m/z):C21H16FN3O,[M+H]+:346.13.
BRM2-22:1HNMR(400MHz,MeOD)δ7.85(d,J=8.0Hz,2H),7.67(dd,J=7.9,4.4Hz,4H),7.18(t,J=8.6Hz,2H),7.06(s,1H),6.93–6.70(m,1H),6.21(dd,J=8.8,4.1Hz,1H).质谱(ESI,m/z):C21H15F2N3O,[M+H]+:364.12.
BRM2-23:1HNMR(400MHz,CDCl3)δ12.62(s,1H),10.10(br,1H),8.30(dd,2H),7.85-7,70(m,5H),7.35-7.27(m,2H),7.03-6.99(m,2H),6.45(d,1H).质谱(ESI,m/z):C23H16FN3O,[M+H]+:370.13.
BRM2-24:1HNMR(400MHz,CDCl3)δ7.82–7.46(m,7H),7.40-7.20(m,2H),6.97-6.84(m,3H).质谱(ESI,m/z):C21H14BrFN2O,[M+H]+:409.03.
BRM2-25:1HNMR(400MHz,MeOD)δ7.87(d,J=7.9Hz,2H),7.73(d,J=8.0Hz,2H),7.67(d,J=8.2Hz,2H),7.47(d,J=8.2Hz,3H),7.16(s,1H),6.93(d,J=4.2Hz,2H).质谱(ESI,m/z):C21H14ClFN2O,[M+H]+:365.08.
BRM2-26:1HNMR(400MHz,DMSO)δ13.81(s,1H),10.68(s,1H),8.98(s,1H),8.59(s,1H),8.15(d,J=6.4Hz,1H),7.95(t,J=15.6Hz,4H),7.64(s,1H),7.60–7.36(m,2H),7.10–6.88(m,2H).质谱(ESI,m/z):C20H14FN3O,[M+H]+:332.11.
BRM2-27:1HNMR(400MHz,MeOD)δ7.84(d,J=7.8Hz,2H),7.47(d,J=9.9Hz,1H),7.20(d,J=7.8Hz,2H),7.15–7.04(m,4H),6.92(d,J=5.7Hz,2H),2.02(s,6H).质谱(ESI,m/z):C23H19FN2O,[M+H]+:359.15.
BRM2-28:1HNMR(400MHz,MeOD)δ7.81(d,J=7.5Hz,2H),7.66(d,J=7.8Hz,2H),7.46(d,J=9.0Hz,1H),7.24(s,2H),7.09(s,1H),7.00(s,1H),6.92(d,J=5.2Hz,2H),2.36(s,6H).质谱(ESI,m/z):C23H19FN2O,[M+H]+:359.15.
BRM2-29:1HNMR(400MHz,MeOD)δ7.80(d,J=8.0Hz,2H),7.64(d,J=8.1Hz,2H),7.52–7.42(m,1H),7.16–7.07(m,2H),7.04(dd,J=8.2,2.0Hz,1H),6.96–6.90(m,2H),6.88(d,J=8.2Hz,1H).质谱(ESI,m/z):C21H15FN2O3,[M+H]+:363.11.
BRM2-30:1HNMR(400MHz,DMSO)δ8.10–7.95(m,6H),7.90(d,J=8.1Hz,2H),7.61(dd,J=9.8,2.5Hz,1H),7.41(s,1H),7.02(td,J=8.5,2.6Hz,1H),6.95(dd,J=8.8,5.0Hz,1H),3.28(s,3H).质谱(ESI,m/z):C22H17FN2O3S,[M+H]+:409.09.
BRM2-31:1HNMR(400MHz,Acetone)δ13.08(s,1H),10.80(s,1H),8.21(s,1H),7.89(d,J=7.4Hz,1H),7.75(dd,J=19.1,7.7Hz,3H),7.61(t,J=8.4Hz,2H),7.55–7.36(m,4H),7.00(dd,J=13.2,4.0Hz,2H).质谱(ESI,m/z):C21H15FN2O,[M+H]+:331.12
BRM2-32:1HNMR(400MHz,Acetone)δ13.05(s,1H),10.80(s,1H),8.21(s,1H),7.90(d,J=7.7Hz,1H),7.77(dd,J=15.3,7.6Hz,3H),7.67–7.56(m,2H),7.53(t,J=7.6Hz,2H),7.48(s,1H),7.43(t,J=7.3Hz,1H),7.05–6.91(m,2H).质谱(ESI,m/z):C21H15FN2O,[M+H]+:331.12.
BRM2-33:1HNMR(400MHz,Acetone)δ12.91(s,1H),10.84(s,1H),7.57(d,J=9.5Hz,1H),7.47(s,1H),7.33(d,J=8.0Hz,2H),7.27(d,J=7.3Hz,1H),7.07–6.87(m,3H),3.26(d,J=4.7Hz,4H),1.65(dd,J=34.6,4.1Hz,6H).质谱(ESI,m/z):C20H20FN3O,[M+H]+:338.16.
BRM2-34:1HNMR(400MHz,MeOD)δ7.50–7.43(m,1H),7.36(s,1H),7.31(t,J=7.8Hz,1H),7.26(d,J=7.6Hz,1H),7.09(d,J=5.1Hz,1H),6.98–6.89(m,3H),3.33–3.25(m,4H),2.81–2.70(m,4H),2.45(s,3H).质谱(ESI,m/z):C20H21FN4O,[M+H]+:353.17.
BRM2-35:1HNMR(400MHz,Acetone)δ12.91(s,1H),10.86(s,1H),7.57(dd,J=9.6,2.9Hz,1H),7.49–7.44(m,1H),7.36–7.29(m,2H),7.28–7.23(m,1H),7.04–6.92(m,3H),3.31–3.21(m,4H),1.75–1.64(m,4H),1.60(ddd,J=11.5,4.7,2.2Hz,2H).质谱(ESI,m/z):C20H20FN3O,[M+H]+:338.16.
BRM2-36:1HNMR(400MHz,MeOD)δ7.51–7.45(m,1H),7.36(dd,J=15.8,7.9Hz,2H),7.27(d,J=7.7Hz,1H),7.11(s,1H),7.01(dd,J=8.2,1.7Hz,1H),6.95–6.90(m,2H),3.32–3.26(m,4H),2.72–2.64(m,4H),2.39(s,3H).质谱(ESI,m/z):C20H21FN4O,[M+H]+:353.17.
BRM2-37:1HNMR(400MHz,MeOD)δ7.60(d,J=8.4Hz,2H),7.49–7.38(m,1H),6.91(t,J=5.0Hz,3H),6.81(d,J=8.5Hz,2H),3.70–3.58(m,2H),3.53(t,J=6.2Hz,2H),2.99–2.86(m,2H),2.84–2.73(m,2H),2.51(s,3H),2.15–2.01(m,2H).质谱(ESI,m/z):C21H23FN4O,[M+H]+:367.19.
BRM2-38:1HNMR(400MHz,Acetone)δ12.76(s,1H),10.92(s,1H),7.74(d,J=8.2Hz,2H),7.54(d,J=9.6Hz,1H),7.19(s,1H),7.08(d,J=8.2Hz,2H),6.96(dt,J=13.5,8.5Hz,2H),3.31(s,4H),2.56(s,4H),2.31(s,3H).质谱(ESI,m/z):C20H21FN4O,[M+H]+:353.17.
BRM2-39:1HNMR(400MHz,Acetone)δ12.72(s,1H),10.93(s,1H),7.72(d,J=8.6Hz,2H),7.54(dd,J=9.6,2.7Hz,1H),7.17(s,1H),7.07(d,J=8.2Hz,2H),7.02–6.89(m,2H),3.39–3.21(m,4H),1.66(dd,J=25.3,4.2Hz,6H).质谱(ESI,m/z):C20H20FN3O,[M+H]+:338.16.
BRM2-40:1HNMR(400MHz,DMSO)δ12.25(s,1H),11.30(s,1H),8.06(d,J=3.5Hz,1H),7.55–7.35(m,2H),6.96(td,J=8.5,3.0Hz,1H),6.90-6.83(m,1H),6.66(d,J=8.6Hz,1H),6.57–6.43(m,1H),6.09(s,1H),3.86-3.80(m,2H),3.55(d,J=4.8Hz,4H),3.38–3.32(m,2H),2.06–1.88(m,2H).质谱(ESI,m/z):C19H20FN5O,[M+H]+:353.17.
BRM2-41:1HNMR(400MHz,Acetone)δ11.62(s,1H),11.10(s,1H),8.06(d,J=4.0Hz,1H),7.55–7.38(m,1H),7.34(dd,J=9.7,3.0Hz,1H),6.99–6.78(m,2H),6.54(dd,J=6.8,5.2Hz,1H),6.46(d,J=8.5Hz,1H),6.01(s,1H),4.98(s,1H),4.58(s,1H),3.70(dd,J=8.7,1.6Hz,1H),3.63–3.48(m,2H),3.31(d,J=8.7Hz,1H),2.13(q,J=9.6Hz,2H).质谱(ESI,m/z):C19H18FN5O,[M+H]+:352.15.
BRM2-42:1HNMR(400MHz,Acetone)δ11.89(s,1H),11.07(s,1H),7.41(dd,J=9.7,3.0Hz,1H),7.32–7.21(m,2H),7.05(d,J=8.0Hz,2H),6.99–6.80(m,3H),6.27(s,1H),3.50–3.40(m,4H),3.40–3.30(m,4H).质谱(ESI,m/z):C19H19FN4O,[M+H]+:339.15.
BRM2-96:1HNMR(400MHz,CDCl3)δ8.97(s,1H),7.91–7.76(m,4H),7.76–7.45(m,3H),7.46–7.30(m,2H),7.21–7.06(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.94(s,1H).质谱(ESI,m/z):C22H15F2N3O2,[M+H]+:392.11。
BRM2-97:1HNMR(400MHz,CDCl3)δ9.04(s,1H),8.28–8.02(m,1H),8.00–7.70(m,4H),7.51(tdd,J=14.9,10.0,3.1Hz,1H),7.42–7.25(m,2H),7.21–6.99(m,3H),6.95(dd,J=15.0,10.1Hz,1H),4.89(s,1H).质谱(ESI,m/z):C22H15F2N3O2,[M+H]+:392.11。
BRM2-98:1HNMR(400MHz,CDCl3)δ9.17(s,1H),8.01–7.76(m,6H),7.76–7.53(m,2H),7.35(dd,J=16.0,3.0Hz,1H),7.31–7.04(m,2H),6.95(dd,J=15.0,10.0Hz,1H),4.97(s,1H).质谱(ESI,m/z):C22H15BrFN3O2,[M+H]+:452.03。
BRM2-99:1HNMR(400MHz,CDCl3)δ9.19(s,1H),8.25–8.04(m,2H),7.98–7.66(m,4H),7.52–7.27(m,3H),7.22–7.06(m,2H),6.95(dd,J=15.0,10.0Hz,1H),4.97(s,1H).质谱(ESI,m/z):C22H15F2N3O2,[M+H]+:392.11。
BRM2-100:1HNMR(400MHz,CDCl3)δ8.95(s,1H),8.02–7.73(m,6H),7.76–7.52(m,2H),7.35(dd,J=16.0,2.9Hz,1H),7.24–7.07(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.92(s,1H).质谱(ESI,m/z):C22H15FClN3O2,[M+H]+:408.08。
BRM2-101:1HNMR(400MHz,CDCl3)δ9.17(s,1H),8.01–7.59(m,4H),7.43(s,4H),7.35(dd,J=16.0,2.9Hz,1H),7.25–7.04(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.93(s,1H).质谱(ESI,m/z):C22H15FClN3O2,[M+H]+:408.08。
BRM2-102:1HNMR(400MHz,CDCl3)δ8.95(s,1H),8.01–7.59(m,6H),7.50–7.21(m,3H),7.22–7.03(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.94(s,1H),2.42(s,3H).质谱(ESI,m/z):C23H18FN3O2,[M+H]+:388.14。
BRM2-103:1HNMR(400MHz,CDCl3)δ9.20(s,1H),8.04–7.61(m,6H),7.48–7.22(m,3H),7.24–7.03(m,2H),6.95(dd,J=15.0,10.0Hz,1H),4.98(s,1H),2.41(s,3H).质谱(ESI,m/z):C23H18FN3O2,[M+H]+:388.14。
BRM2-104:1HNMR(400MHz,CDCl3)δ9.10(s,1H),7.98–7.58(m,6H),7.55–7.26(m,2H),7.31–7.02(m,3H),6.95(dd,J=15.0,10.0Hz,1H),4.96(s,1H).质谱(ESI,m/z):C23H15F4N3O2,[M+H]+:442.12。
BRM2-105:1HNMR(400MHz,CDCl3)δ9.58(s,1H),8.07–7.67(m,4H),7.59–7.41(m,1H),7.38–7.22(m,2H),7.18–7.04(m,3H),6.95(dd,J=15.0,10.1Hz,1H).质谱(ESI,m/z):C22H14F3N3O2,[M+H]+:410.10。
BRM2-106:1HNMR(400MHz,CDCl3)δ9.00(s,1H),8.10–7.58(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.20–7.00(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.43(s,1H),2.10–1.96(m,3H),1.97–1.78(m,6H),1.81–1.52(m,6H).质谱(ESI,m/z):C26H26FN3O2,[M+H]+:432.20。
BRM2-107:1HNMR(400MHz,CDCl3)δ8.93(s,1H),8.08–7.65(m,6H),7.35(dd,J=16.0,2.9Hz,1H),7.25–7.04(m,4H),6.95(dd,J=15.0,10.1Hz,1H),4.94(s,1H),3.79(s,3H).质谱(ESI,m/z):C23H18FN3O2,[M+H]+:404.13。
BRM2-108:1HNMR(400MHz,CDCl3)δ8.94(s,1H),8.08–7.59(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.25–7.03(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.95(s,1H),4.54–3.86(m,2H),2.96–2.59(m,2H),2.37(p,J=15.6Hz,1H),1.90–1.69(m,2H),1.67–1.40(m,1H),1.37–0.89(m,3H).质谱(ESI,m/z):C22H22FN3O2,[M+H]+:380.17。
BRM2-109:1HNMR(400MHz,CDCl3)δ8.92(s,1H),8.82(d,J=15.0Hz,2H),8.07–7.62(m,6H),7.35(dd,J=16.0,2.9Hz,1H),7.35(dd,J=16.0,2.9Hz,1H),7.17–7.00(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.57(s,1H).质谱(ESI,m/z):C21H15FN4O2,[M+H]+:375.12。
BRM2-110:1HNMR(400MHz,CDCl3)δ8.93(s,1H),8.03–7.72(m,6H),7.68–7.46(m,3H),7.35(dd,J=16.0,2.9Hz,1H),7.27(s,1H),7.22–7.05(m,1H),6.95(dd,J=15.0,10.1Hz,1H).质谱(ESI,m/z):C22H16FN3O2,[M+H]+:374.12。
BRM2-111:1HNMR(400MHz,CDCl3)δ9.15–8.80(m,2H),8.09(dd,J=15.0,3.0Hz,1H),7.97–7.65(m,4H),7.55–7.27(m,2H),7.28–7.06(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.94(s,1H),2.55(s,3H)质谱(ESI,m/z):C22H17FN4O2,[M+H]+:389.13。
BRM2-112:1HNMR(400MHz,CDCl3)δ8.97–8.61(m,2H),8.53–8.28(m,1H),8.14–7.66(m,6H),7.35(dd,J=16.0,2.9Hz,1H),7.22–7.04(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.92(s,1H).质谱(ESI,m/z):C21H15FN4O2,[M+H]+:375.12。
BRM2-113:1HNMR(400MHz,CDCl3)δ9.79(s,1H),7.79(ddd,J=18.3,9.0,4.5Hz,5H),7.50–7.27(m,2H),7.25–7.01(m,3H),6.95(dd,J=7.4,5.0Hz,1H),4.96(s,1H),3.87(d,J=16.0Hz,6H).质谱(ESI,m/z):C24H20FN3O4,[M+H]+:434.14。
BRM2-114:1HNMR(400MHz,CDCl3)δ9.00(s,1H),8.00–7.62(m,5H),7.49–7.20(m,3H),7.17–7.04(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.93(s,1H).质谱(ESI,m/z):C22H14F3N3O2,[M+H]+:410.10。
BRM2-115:1HNMR(400MHz,CDCl3)δ8.31(s,1H),7.98–7.59(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.27–7.07(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.98(s,1H),3.98–3.38(m,4H),3.00(tt,J=17.7,15.8Hz,1H),2.30–1.65(m,4H).质谱(ESI,m/z):C21H20FN3O3,[M+H]+:382.15。
BRM2-116:1HNMR(400MHz,CDCl3)δ8.79(s,1H),8.24–7.65(m,4H),7.49–7.21(m,2H),7.20–7.07(m,1H),6.95(dd,J=15.0,10.1Hz,1H),2.48–1.88(m,1H),1.21–0.30(m,4H).质谱(ESI,m/z):C19H16FN3O2,[M+H]+:338.12。
BRM2-117:1HNMR(400MHz,CDCl3)δ8.67(s,1H),8.15–7.69(m,5H),7.55–7.22(m,2H),7.21–7.01(m,2H),6.95(dd,J=15.0,10.1Hz,1H),6.71(t,J=15.0Hz,1H),4.99(s,1H).质谱(ESI,m/z):C20H14FN3O3,[M+H]+:364.10。
BRM2-118:1HNMR(400MHz,CDCl3)δ8.98(s,1H),8.02–7.74(m,5H),7.67–7.44(m,1H),7.35(dd,J=16.0,2.9Hz,1H),7.33(d,J=2.9Hz,1H),7.24–6.69(m,5H),4.94(s,1H),4.05(q,J=11.8Hz,2H),1.34(t,J=11.8Hz,3H).质谱(ESI,m/z):C24H20FN3O3,[M+H]+:418.15。
BRM2-119:1HNMR(400MHz,CDCl3)δ8.82(s,1H),8.30(dd,J=15.0,3.0Hz,1H),8.08–7.65(m,5H),7.35(dd,J=16.0,2.9Hz,1H),7.27–7.07(m,3H),6.95(dd,J=15.0,10.1Hz,1H),4.95(s,1H).质谱(ESI,m/z):C20H14FN3O2S,[M+H]+:380.08。
BRM2-120:1HNMR(400MHz,CDCl3)δ7.95–7.48(m,4H),7.34(dd,J=16.0,2.9Hz,1H),7.20–7.00(m,1H),7.07–6.73(m,1H),2.68–2.13(m,4H),2.10–1.67(m,3H).质谱(ESI,m/z):C20H18FN3O2,[M+H]+:352.14。
BRM2-121:1HNMR(400MHz,CDCl3)δ9.14(dd,J=3.0,0.5Hz,1H),8.93(s,1H),8.85–8.61(m,1H),8.21(dt,J=15.0,3.0Hz,1H),8.02–7.63(m,4H),7.58–7.30(m,2H),7.22–7.09(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.93(s,1H).质谱(ESI,m/z):C21H15FN4O2,[M+H]+:375.12。
BRM2-122:1HNMR(400MHz,CDCl3)δ8.78(s,1H),8.05(s,1H),7.93–7.65(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.28–7.01(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.94(s,1H),2.43(s,3H).质谱(ESI,m/z):C20H15FN4O3,[M+H]+:379.11。
BRM2-123:1HNMR(400MHz,CDCl3)δ8.95(s,1H),8.43(d,J=15.0Hz,1H),8.08–7.72(m,5H),7.62(d,J=2.9Hz,1H),7.35(dd,J=16.0,2.9Hz,1H),7.27–7.03(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.93(s,1H).质谱(ESI,m/z):C21H20ClFN4O2,[M+H]+:409.08。
BRM2-124:1HNMR(400MHz,CDCl3)δ9.96(s,1H),9.10(d,J=15.0Hz,1H),8.89(d,J=15.0Hz,1H),8.78(s,1H),8.07–7.58(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.22–7.06(m,2H),6.97–6.69(m,1H),4.90(s,1H).质谱(ESI,m/z):C20H14FN5O2,[M+H]+:376.11。
BRM2-125:1HNMR(400MHz,CDCl3)δ8.96(s,1H),7.97–7.66(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.20–7.01(m,2H),6.95(dd,J=15.0,10.1Hz,1H),6.46(dt,J=6.9,2.5Hz,3H),4.93(s,1H),3.77(s,6H).质谱(ESI,m/z):C24H20FN3O4,[M+H]+:434.14。
BRM2-126:1HNMR(400MHz,CDCl3)δ8.23(s,1H),8.05–7.58(m,4H),7.44–7.15(m,1H),7.31–6.82(m,3H),4.31(s,1H),2.32(td,J=15.0,0.8Hz,2H),2.00–1.50(m,2H),0.98(t,J=13.1Hz,3H).质谱(ESI,m/z):C19H18FN3O2,[M+H]+:340.14。
BRM2-127:1HNMR(400MHz,CDCl3)δ8.19(s,1H),7.93–7.59(m,4H),7.35(dd,J=16.0,2.9Hz,1H),7.18–7.06(m,2H),6.95(dd,J=15.0,10.1Hz,1H),4.93(s,1H),1.23(s,9H).质谱(ESI,m/z):C20H20FN3O2,[M+H]+:354.15。
BRM2-128:1HNMR(400MHz,CDCl3)δ8.99(s,1H),8.07–7.69(m,4H),7.46–7.03(m,8H),6.95(dd,J=15.0,10.1Hz,1H),4.95(s,1H),3.23–2.68(m,4H).质谱(ESI,m/z):C24H20FN3O2,[M+H]+:402.15。
BRM2-129:1HNMR(400MHz,CDCl3)δ7.32(dd,J=16.0,2.9Hz,1H),7.21–7.01(m,2H),6.92(dd,J=14.9,10.0Hz,1H),5.93(s,1H),4.88(s,1H),3.55(p,J=15.2Hz,1H),2.80–2.24(m,4H),2.17(s,3H),1.83(dddt,J=62.2,24.8,15.3,11.1Hz,4H).质谱(ESI,m/z):C16H19FN4O2,[M+H]+:319.15。
BRM2-130:1HNMR(400MHz,CDCl3)δ9.09(s,1H),7.61–7.03(m,4H),7.03–6.58(m,4H),4.91(s,1H),3.44(t,J=10.3Hz,4H),2.35(t,J=10.3Hz,4H),2.21(s,3H).质谱(ESI,m/z):C21H22FN5O2,[M+H]+:396.18。
BRM2-131:1HNMR(400MHz,CDCl3)δ7.80(d,J=15.0Hz,1H),7.35(dd,J=16.0,2.9Hz,1H),7.25–6.99(m,2H),7.04–6.72(m,2H),4.45(s,1H),3.94(s,3H).质谱(ESI,m/z):C14H12FN5O2,[M+H]+:302.10。
BRM2-132:1HNMR(400MHz,CDCl3)δ8.04(dd,J=15.0,2.9Hz,1H),7.55(td,J=15.0,3.0Hz,1H),7.35(dd,J=16.0,2.9Hz,1H),7.27–6.87(m,4H),6.73(td,J=15.0,3.0Hz,1H),4.87(s,1H),3.99(t,J=10.0Hz,4H),3.36(t,J=10.0Hz,4H).质谱(ESI,m/z):C19H18FN5O2,[M+H]+:368.14。
BRM2-133:1HNMR(400MHz,CDCl3)δ7.33(dd,J=16.0,2.9Hz,1H),7.22–7.00(m,2H),6.93(dd,J=15.0,10.1Hz,1H),4.87(s,1H),3.42–2.96(m,6H),2.81(t,J=10.1Hz,2H),2.17(s,3H),2.02–1.55(m,2H).质谱(ESI,m/z):C16H19FN4O2,[M+H]+:319.15。
BRM2-134:1HNMR(400MHz,CDCl3)δ7.35(dd,J=16.0,3.0Hz,1H),7.15–7.04(m,2H),6.94(dd,J=15.0,10.1Hz,1H),4.91(s,1H),3.52–2.97(m,8H),1.42(s,9H).质谱(ESI,m/z):C19H23FN4O4,[M+H]+:391.17。
BRM2-135:1HNMR(400MHz,CDCl3)δ7.35(dd,J=16.0,2.9Hz,1H),7.24–7.02(m,2H),6.95(dd,J=15.0,10.1Hz,1H),6.29(s,1H),4.92(s,1H),3.75–3.32(m,4H),3.11–2.88(m,2H),2.21–1.78(m,3H),1.55(ddt,J=24.8,15.3,11.1Hz,2H),1.42(s,9H).质谱(ESI,m/z):C21H27FN4O4,[M+H]+:419.20。
BRM2-136:1HNMR(400MHz,CDCl3)δ7.53–7.20(m,3H),7.27–6.89(m,5H),6.82(s,1H),4.83(s,1H),4.11(s,2H).质谱(ESI,m/z):C17H13F2N3O2,[M+H]+:330.10。
BRM2-137:1HNMR(400MHz,CDCl3)δ7.35(dd,J=16.0,2.9Hz,1H),7.21–6.82(m,5H),6.78–6.55(m,2H),6.35(s,1H),4.65(d,J=50.8Hz,2H),3.37(td,J=15.4,0.8Hz,2H),2.79(td,J=15.4,0.8Hz,2H)质谱(ESI,m/z):C18H16FN3O3,[M+H]+:342.12。
BRM2-138:1HNMR(400MHz,CDCl3)δ7.35(dd,J=16.0,2.9Hz,1H),7.24(s,1H),7.14(dd,J=15.1,2.9Hz,1H),7.10–7.02(m,1H),6.99–6.89(m,3H),6.82–6.66(m,2H),4.64(s,1H),4.11(s,2H).质谱(ESI,m/z):C17H14FN3O3,[M+H]+:328.10。
BRM2-139:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.62–7.22(m,3H),7.27–6.80(m,7H),3.31(t,J=10.4Hz,2H),2.90(t,J=10.4Hz,2H).质谱(ESI,m/z):C20H17FN4O2,[M+H]+:365.13。
BRM2-140:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.46–7.27(m,3H),7.18–6.83(m,6H),3.37(td,J=15.4,0.8Hz,2H),2.79(td,J=15.4,0.8Hz,2H).质谱(ESI,m/z):C18H15ClFN3O2,[M+H]+:360.08。
BRM2-141:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.31–7.07(m,6H),7.03(t,J=8.2Hz,2H),6.98(dd,J=15.0,10.1Hz,1H),3.37(td,J=15.4,0.8Hz,2H),2.79(td,J=15.4,0.8Hz,2H).质谱(ESI,m/z):C18H16FN3O2,[M+H]+:326.12。
BRM2-142:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.48–7.14(m,1H),7.25–6.65(m,4H),3.25(t,J=15.2Hz,2H),1.75–1.20(m,2H),0.88(t,J=13.2Hz,3H).质谱(ESI,m/z):C13H14FN3O3,[M+H]+:264.11。
BRM2-143:1HNMR(400MHz,6d-DMSO)δ7.37–7.12(m,3H),7.10–6.78(m,6H),4.61(s,3H),3.19(s,3H).质谱(ESI,m/z):C18H16FN3O2,[M+H]+:326.12。
BRM2-144:1HNMR(400MHz,6d-DMSO)δ7.45–7.22(m,3H),7.20–6.91(m,6H),4.67(s,3H),3.07(q,J=12.6Hz,2H),1.17(t,J=12.6Hz,3H).质谱(ESI,m/z):C19H18FN3O3,[M+H]+:340.14。
BRM2-145:1HNMR(400MHz,6d-DMSO)δ7.43–7.25(m,6H),7.19–7.03(m,3H),6.98(dd,J=15.0,10.1Hz,1H),4.67(s,2H),3.77(hept,J=12.0Hz,1H),1.26(d,J=12.0Hz,6H).质谱(ESI,m/z):C20H20FN3O3,[M+H]+:354.15。
BRM2-146:1HNMR(400MHz,6d-DMSO)δ7.43(d,J=8.9Hz,1H),7.41–7.20(m,11H),7.18–6.87(m,3H),4.67(s,4H).质谱(ESI,m/z):C24H20FN3O3,[M+H]+:402.15。
BRM2-147:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),7.33(dt,J=25.8,12.9Hz,1H),7.28–6.70(m,9H),4.81(t,J=14.2Hz,1H),3.66(s,3H),3.10(ddd,J=103.0,24.8,14.2Hz,2H).质谱(ESI,m/z):C20H18FN3O4,[M+H]+:384.13。
BRM2-148:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.22–6.76(m,4H),4.51(t,J=12.9Hz,1H),3.66(s,3H),2.60(td,J=16.0,1.3Hz,2H),2.38–1.88(m,5H).质谱(ESI,m/z):C16H18FN3O4S,[M+H]+:368.10。
BRM2-149:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),7.56–7.30(m,2H),7.27–6.78(m,3H),4.51(t,J=6.6Hz,1H),3.66(s,3H),2.89(dd,J=17.4,6.1Hz,2H),2.80(s,3H),2.56–2.42(m,2H).质谱(ESI,m/z):C16H18FN3O6S,[M+H]+:400.09。
BRM2-150:1HNMR(400MHz,6d-DMSO)δ7.35(dd,J=16.0,2.9Hz,1H),7.22–6.87(m,4H),4.43–4.08(m,1H),4.01–3.17(m,5H),2.40–1.86(m,2H),1.83–1.43(m,2H).质谱(ESI,m/z):C16H16FN3O4,[M+H]+:334.11。
BRM2-151:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),9.05(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.28–6.85(m,6H),6.75–6.50(m,2H),4.81(t,J=6.9Hz,1H),3.11(ddd,J=103.0,24.8,6.8Hz,2H).质谱(ESI,m/z):C20H18FN3O5,[M+H]+:400.12。
BRM2-152:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),8.47(d,J=0.5Hz,1H),7.35(dd,J=16.0,1.6Hz,2H),7.21–6.78(m,4H),4.68(t,J=7.8Hz,1H),3.66(s,3H),3.10(dd,J=24.8,7.8Hz,1H),2.44(dd,J=24.8,7.8Hz,1H).质谱(ESI,m/z):C17H16FN5O4,[M+H]+:374.12。
BRM2-153:1HNMR(400MHz,6d-DMSO)δ9.34(s,1H),7.32(dd,J=16.0,2.9Hz,1H),7.17–6.80(m,4H),4.19(d,J=4.8Hz,1H),3.64(s,3H),2.80(tqd,J=15.5,13.0,4.8Hz,1H),1.78–1.37(m,2H),1.21–0.75(m,6H).质谱(ESI,m/z):C17H20FN3O4,[M+H]+:350.14。
BRM2-154:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),7.46–7.24(m,1H),7.28–6.76(m,9H),5.11(t,J=12.2Hz,1H),3.98–3.42(m,4H),3.39–2.83(m,2H),2.14–1.67(m,4H).质谱(ESI,m/z):C23H23FN4O3,[M+H]+:423.18。
BRM2-155:1HNMR(400MHz,6d-DMSO)δ9.38(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.32–7.21(m,1H),7.15–6.92(m,7H),4.81(t,J=11.7Hz,1H),3.64(tdd,J=10.2,8.3,3.9Hz,6H),3.51–3.12(m,3H),3.04(dd,J=24.8,11.7Hz,1H).质谱(ESI,m/z):C23H23FN4O4,[M+H]+:439.17。
BRM2-156:1HNMR(400MHz,6d-DMSO)δ9.33(s,1H),7.31(dd,J=16.0,2.9Hz,1H),7.17–6.62(m,4H),6.11(s,2H),4.67–4.26(m,1H),3.75(dd,J=9.9,8.6Hz,2H),3.59(dd,J=9.8,8.8Hz,4H),3.39(dd,J=9.7,8.8Hz,2H),2.40–1.76(m,4H).质谱(ESI,m/z):C19H22FN5O5,[M+H]+:420.16。
BRM2-157:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.28–6.75(m,8H),3.37(td,J=15.4,0.8Hz,2H),2.79(td,J=15.4,0.8Hz,2H).质谱(ESI,m/z):C18H15F2N3O2,[M+H]+:344.11。
BRM2-158:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.22–6.75(m,3H),4.26(dd,J=103.0,24.8Hz,4H),0.92(s,3H).质谱(ESI,m/z):C15H16FN3O3,[M+H]+:306.12。
BRM2-159:1HNMR(400MHz,6d-DMSO)δ8.98(s,1H),8.21–7.73(m,2H),7.35(dd,J=16.0,2.9Hz,1H),7.21–6.85(m,6H),6.08(s,2H),3.37(t,J=10.2Hz,2H),2.79(t,J=10.2Hz,2H).质谱(ESI,m/z):C19H17FN4O3,[M+H]+:369.13。
BRM2-160:1HNMR(400MHz,6d-DMSO)δ7.35(dd,J=7.9,1.4Hz,1H),7.12(td,J=7.8,1.4Hz,1H),7.05(s,1H),6.98(dd,J=7.4,5.0Hz,1H),5.99(s,2H),5.57(s,1H).质谱(ESI,m/z):C9H8FN3O,[M+H]+:194.07。
BRM2-161:1HNMR(400MHz,6d-DMSO)δ7.35(dd,J=16.0,2.9Hz,1H),7.23–6.84(m,3H),5.74(s,1H),2.36(td,J=16.1,0.7Hz,2H),1.89–1.38(m,2H),0.98(t,J=13.1Hz,3H).质谱(ESI,m/z):C13H14FN3O2,[M+H]+:264.11。
BRM2-162:1HNMR(400MHz,6d-DMSO)δ8.03–7.80(m,1H),7.73–7.45(m,2H),7.45–7.25(m,1H),7.24–6.85(m,2H),5.99(s,1H).质谱(ESI,m/z):C16H12FN3O2,[M+H]+:298.09。
BRM2-163:1HNMR(400MHz,6d-DMSO)δ9.68(s,1H),7.92–7.58(m,2H),7.35(dd,J=16.0,2.9Hz,1H),7.24–6.72(m,5H),5.98(s,1H).质谱(ESI,m/z):C16H12FN3O3,[M+H]+:314.09。
BRM2-164:1HNMR(400MHz,6d-DMSO)δ9.05(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.26–6.78(m,5H),6.78–6.56(m,2H),5.83(s,1H),3.80(s,2H).质谱(ESI,m/z):C17H14FN3O3,[M+H]+:328.10。
BRM2-165:1HNMR(400MHz,6d-DMSO)δ9.14(dd,J=3.0,0.5Hz,1H),8.92–8.60(m,1H),8.30(dt,J=15.0,3.0Hz,1H),7.59(t,J=15.0Hz,1H),7.50–7.30(m,1H),7.25–6.80(m,3H),5.37(s,1H).质谱(ESI,m/z):C15H11FN4O2,[M+H]+:299.09。
BRM2-166:1HNMR(400MHz,6d-DMSO)δ9.96(s,1H),9.10(d,J=15.0Hz,1H),8.89(d,J=15.0Hz,1H),7.32(dt,J=46.6,23.3Hz,1H),7.27–6.55(m,3H),5.80(s,1H).质谱(ESI,m/z):C14H10FN5O2,[M+H]+:300.08。
BRM2-167:1HNMR(400MHz,6d-DMSO)δ9.05(s,1H),7.35(dd,J=16.0,2.9Hz,1H),7.20–6.86(m,5H),6.76–6.54(m,2H),5.65(s,1H),3.25–2.49(m,4H).质谱(ESI,m/z):C18H16FN3O3,[M+H]+:342.12。
BRM2-168:1HNMR(400MHz,6d-DMSO)δ7.50–7.21(m,2H),7.27–6.85(m,4H),5.85(s,2H),3.80(s,2H).质谱(ESI,m/z):C17H13F2N3O2,[M+H]+:330.10。
BRM2-169:1HNMR(400MHz,6d-DMSO)δ8.11–7.70(m,1H),7.55–7.24(m,2H),7.30–6.50(m,5H),5.99(s,1H).质谱(ESI,m/z):C16H12FN3O3,[M+H]+:314.09。
BRM2-170:1HNMR(400MHz,6d-DMSO)δ7.91–7.72(m,1H),7.72–7.49(m,1H),7.35(dd,J=16.0,2.9Hz,1H),7.15–6.68(m,1H),5.69(s,1H).质谱(ESI,m/z):C17H11F4N3O2,[M+H]+:366.08。
BRM2-171:1HNMR(400MHz,6d-DMSO)δ8.19–7.86(m,1H),7.77–7.49(m,1H),7.35(dd,J=16.0,2.9Hz,1H),7.17–6.65(m,1H),5.98(s,1H).质谱(ESI,m/z):C16H11BrFN3O3,[M+H]+:376.00。
BRM2-172:1HNMR(400MHz,6d-DMSO)δ7.42(d,J=15.0Hz,1H),7.35(dd,J=16.0,2.9Hz,1H),7.21–7.07(m,1H),7.06–6.91(m,2H),6.70(d,J=15.0Hz,1H),6.00(s,1H).质谱(ESI,m/z):C13H10FN5O2,[M+H]+:288.08。
BRM2-173:1HNMR(400MHz,6d-DMSO)δ7.44(dd,J=7.9,1.4Hz,1H),7.35(dd,J=7.9,1.4Hz,1H),7.27(td,J=7.8,1.4Hz,1H),7.12(td,J=7.8,1.4Hz,1H),7.05(s,1H),6.97(ddd,J=7.6,4.9,3.9Hz,2H),6.00(s,1H).质谱(ESI,m/z):C16H11F2N3O2,[M+H]+:332.08。
BRM2-174:1HNMR(400MHz,6d-DMSO)δ7.35(dd,J=16.0,2.9Hz,1H),7.22–7.07(m,1H),7.05(s,1H),6.98(dd,J=15.0,10.1Hz,1H),5.73(s,1H).质谱(ESI,m/z):C16H12FN3O3,[M+H]+:314.09。质谱(ESI,m/z):C18H13F2N5O2,[M+H]+:370.10。
实施例9细胞活力实验方法测定本发明所述化合物的药效活性:
使用四唑盐(MTT)的方法测定本发明所述化合物的药效活性,使用的细胞系为H1299细胞,该细胞系BRG1基因缺失(BRG1-),而BRM基因非缺失(BRM+),即该细胞系的细胞内不能表达BRG1蛋白,但可正常表达BRM蛋白。能在细胞内阻止BRM蛋白与染色体相互作用的小分子,即可阻止BRM蛋白行使细胞内的功能。根据协同致死规律,在BRGI基因缺失的细胞里,阻止BRM蛋白的功能,则会导致细胞死亡,实现小分予杀死癌细胞的作用。
实验具体操作步骤如下:
(1)将不同的实验细胞系传代分板到96孔板中。为了防止边际效应96孔板的四周加入100μL的PBS作空白,其中使用的细胞系为H1299细胞(BRG1-/BRM+细胞系)。
(2)细胞贴壁生长40-50%时,加入不同浓度的药物分子和DMSO作为对照。小分子处理过的细胞继续培养3-4天。中途换一次加小分子的培养基。
(3)对照组DMSO处理过的96孔板细胞长满后,每孔中加入20μL的MTT母液(5mg/mL)。
(4)将细胞板继续放回37℃的C2O培养箱中孵育4小时。
(5)吸去MTT液,每孔中加入150μLDMSO。
(6)室温下将96孔板避光放入震荡摇床中,15min直到将紫色结晶全部溶解。
(7)利用SpectraMaxM5多孔读板仪(MolecularDevices,美国)在490nm波长下,测定每孔的吸光值(OD)。
按照常规检测方法,确定了各化合物(小分子)的EC50值,结果总结在表l中。
表1
Claims (7)
3.根据权利要求1-2任意一项所述的式(Ⅲ)的化合物或其药学上可接受的盐,其特征在于,R2选自H或C1-6烷基。
5.一种药物组合物,包括权利要求1所述的式(Ⅲ)的化合物或其药学上可接受的盐以及药学上可接受的辅料。
6.权利要求1所述的式(Ⅲ)的化合物或其药学上可接受的盐在制备预防和/或治疗癌症药物中的应用。
7.权利要求6所述的应用,所述的癌症包括淋巴瘤,母细胞瘤,髓母细胞瘤,神经内分泌肿瘤,类癌肿瘤,胃泌素瘤,胰岛细胞癌,间皮瘤,神经鞘瘤,听神经瘤,脑膜瘤,黑素瘤,鳞状细胞癌,肺癌,腹膜癌,胃癌,肠癌,胰腺癌,卵巢癌,肝癌,膀胱癌,乳腺癌,子宫癌,唾液腺癌,肾癌,前列腺癌,外阴癌,甲状腺癌,肛门癌,阴茎癌,食管癌和胆道肿瘤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011433095.8A CN112480079B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711091268.0A CN109748873B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011433095.8A CN112480079B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711091268.0A Division CN109748873B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112480079A CN112480079A (zh) | 2021-03-12 |
CN112480079B true CN112480079B (zh) | 2022-03-11 |
Family
ID=66401885
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711091268.0A Active CN109748873B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011437196.2A Active CN112480005B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011433438.0A Active CN112457255B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011433095.8A Active CN112480079B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711091268.0A Active CN109748873B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011437196.2A Active CN112480005B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
CN202011433438.0A Active CN112457255B (zh) | 2017-11-08 | 2017-11-08 | 化合物及其治疗癌症的用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11332461B2 (zh) |
EP (1) | EP3705476B1 (zh) |
CN (4) | CN109748873B (zh) |
WO (1) | WO2019091277A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4053127A4 (en) * | 2019-10-31 | 2023-11-29 | Holosmedic | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER |
EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
TW202206409A (zh) * | 2020-04-27 | 2022-02-16 | 南韓商奧士擇破利悟股份有限公司 | 用於ubr盒結構域配體之化合物以及醫藥組成物 |
EP4173485A1 (en) * | 2021-10-27 | 2023-05-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein aggregation inhibiting compounds for plant disease control |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264377A (zh) * | 1997-05-22 | 2000-08-23 | G·D·西尔公司 | 用作p38激酶抑制剂的取代的吡唑化合物 |
CN1342157A (zh) * | 1998-11-20 | 2002-03-27 | G.D.西尔公司 | 用作ASp38激酶抑制剂的取代吡唑 |
WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
WO2008145681A2 (en) * | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003237446A1 (en) * | 2002-06-05 | 2003-12-22 | Pharmacia Corporation | Pyrazole-derivatives as p38 kinase inhibitors |
TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
WO2008046072A2 (en) * | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
CL2008000119A1 (es) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
KR20110017407A (ko) * | 2008-05-30 | 2011-02-21 | 포스터 휠러 에너지아 오와이 | 순산소 연소에 의해 전력을 생성하는 방법과 시스템 |
TW201004941A (en) * | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
JP2012102018A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | アミド化合物 |
US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
WO2016040449A1 (en) * | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
PL3315492T3 (pl) * | 2015-06-23 | 2021-04-06 | Kissei Pharmaceutical Co., Ltd. | Pochodna pirazolu lub jej farmaceutycznie dopuszczalna sól |
CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
-
2017
- 2017-11-08 CN CN201711091268.0A patent/CN109748873B/zh active Active
- 2017-11-08 CN CN202011437196.2A patent/CN112480005B/zh active Active
- 2017-11-08 CN CN202011433438.0A patent/CN112457255B/zh active Active
- 2017-11-08 CN CN202011433095.8A patent/CN112480079B/zh active Active
-
2018
- 2018-10-22 WO PCT/CN2018/111154 patent/WO2019091277A1/zh unknown
- 2018-10-22 US US16/761,091 patent/US11332461B2/en active Active
- 2018-10-22 EP EP18877108.3A patent/EP3705476B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264377A (zh) * | 1997-05-22 | 2000-08-23 | G·D·西尔公司 | 用作p38激酶抑制剂的取代的吡唑化合物 |
CN1342157A (zh) * | 1998-11-20 | 2002-03-27 | G.D.西尔公司 | 用作ASp38激酶抑制剂的取代吡唑 |
WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
WO2008145681A2 (en) * | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3705476B1 (en) | 2024-09-04 |
CN112457255B (zh) | 2022-08-19 |
CN112457255A (zh) | 2021-03-09 |
CN112480005A (zh) | 2021-03-12 |
US11332461B2 (en) | 2022-05-17 |
CN109748873B (zh) | 2021-02-02 |
CN109748873A (zh) | 2019-05-14 |
CN112480079A (zh) | 2021-03-12 |
WO2019091277A1 (zh) | 2019-05-16 |
CN112480005B (zh) | 2022-08-19 |
EP3705476A4 (en) | 2020-09-09 |
US20200354342A1 (en) | 2020-11-12 |
EP3705476A1 (en) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112480079B (zh) | 化合物及其治疗癌症的用途 | |
KR20210143803A (ko) | Tead 전사인자의 신규한 소분자 저해제 | |
EP3919488A1 (en) | Immunomodulator | |
CN111961034A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
EP2915810A1 (en) | N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof | |
CA3005118A1 (en) | Process for making benzoxazepin compounds | |
JP2023513373A (ja) | P2x3修飾薬 | |
ES2927529T3 (es) | Compuesto heterocíclico condensado | |
CN116390728A (zh) | 喹唑啉衍生物及其制备方法和用途 | |
JP2022549030A (ja) | 複素環アミド化合物、その薬学的に許容される塩およびその調製方法と使用 | |
EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
WO2015113521A1 (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
WO2016138882A1 (zh) | 七元环小檗碱类似物及其药物组合物、制备方法和用途 | |
RU2542980C2 (ru) | Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии | |
KR102606167B1 (ko) | 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용 | |
KR20200102529A (ko) | 삼환식 화합물 및 암의 치료에서의 이의 용도 | |
JP2018501282A (ja) | チアゾール誘導体の製造方法 | |
CN111848528B (zh) | 一种预防和/或治疗癌症的化合物及其制备方法和应用 | |
JP4328873B2 (ja) | 放射線増感剤 | |
KR101589632B1 (ko) | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 | |
CN111454278A (zh) | Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用 | |
KR20240046553A (ko) | Sting 길항제로서의 소분자 우레아 유도체 | |
CN113831353A (zh) | 一种vegfr3小分子抑制剂及其在抗肿瘤药物中的应用 | |
BR112018010473B1 (pt) | Composto, composição farmacêutica e uso do composto | |
JP2019519615A (ja) | 5−ht1a受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |